Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Adults With IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial
American Society of Nephrology (ASN) Kidney Week – 2024
Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series
Poster
Published on October 25, 2024
About the research
Summary
Background
- Sparsentan is a non-immunosuppressive, Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in adults with IgA nephropathy who are at risk for disease progression1-5
- Previous clinical data from PROTECT open-label extension (OLE) period indicated that adding an SGLT2i to stable sparsentan demonstrated a benefit on proteinuria reduction and was generally well tolerated6
- Real-world evidence on the use of sparsentan and SGLT2is is limited1
Aim
- The objective of this case series was to report the clinical features and treatment responses of 4 patients with IgA nephropathy receiving sparsentan in combination with an SGLT2i in a real-world setting1
Approach
- Patients were selected by their healthcare professional (HCP) for inclusion in this case series1
- Eligibility criteria included1:
- Biopsy-proven IgA nephropathy
- Sparsentan treatment for ≥3 months
- Received an SGLT2i concurrently with sparsentan
- Patient consent
- Duration of follow-up on sparsentan ranged from 3 to 10 months, with all patients receiving ongoing sparsentan and SGLT2i combination treatment at last follow-up1
- All patients received sparsentan in combination with the SGLT2i dapagliflozin1
Key findings
- Combining sparsentan and the SGLT2i, dapagliflozin1:
- Demonstrated a rapid decrease in proteinuria (urine protein-creatinine ratio [UPCR]) from sparsentan initiation to follow-up
- Led to an improvement in proteinuria regardless of estimated glomerular filtration rate (eGFR) or UPCR at sparsentan initiation
- Resulted in further decreases in proteinuria and albuminuria compared to the end of the previous treatment
- Showed stable eGFR and blood pressure
- Combining both treatments was generally well tolerated with no treatment discontinuations due to safety concerns1
Read more about concomitant use of sparsentan and an SGLT2i in the SPARTACUS study and PROTECT OLE period.
Conclusions
- Overall, findings from this case series support the safety and effectiveness of sparsentan in combination with the SGLT2i dapagliflozin in patients with IgA nephropathy1
Related content
Footnotes
DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; HCP, healthcare professional; IgA, immunoglobulin A; OLE, open-label extension; SGLT2i, sodium-glucose cotransporter-2 inhibitor; UPCR, urine protein-creatinine ratio.
- Ravipati P et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO906.
- Kohan DE et al. Clin Sci. 2024;138(11):645-662.
- Trachtman H et al. Expert Rev Clin Immunol. 2024;20(6):571-576.
- FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9/2024.
- FILSPARI® (sparsentan) Summary of Product Characteristics. Paris, France: Vifor France. 7/2024.
- Preciado P et al. Poster presented at: World Congress of Nephrology (WCN) 2024; April 13-16, 2024; Buenos Aires, Argentina. WCN24-AB-752.
MA-SP-24-0135 | November 2024